TRISH, or the Translational Institute of Space Health, has named three fellows to its new program. Photo via bcm.edu

Three Texas scientists have been selected for a Houston organization's prestigious program focused on space health.

TRISH, or the Translational Research Institute for Space Health, which is based out of Houston-based Baylor College of Medicine, has announced its selections for the TRISH 2023 fellowship. The program, announced last fall, is in partnership with California Institute of Technology and Massachusetts Institute of Technology.

“Supporting the next generation of space health researchers ensures that we will have the best possible data to make evidence-based decisions about managing human systems risk for exploration class missions,” says Dr. Jennifer Fogarty, TRISH’s chief scientific officer, in a news release. “By investing in TRISH postdoctoral fellows, we’re investing in future experts who will strive to solve the complex problems and risks associated with human space exploration. We are thrilled to welcome these accomplished early-career scientists to the TRISH community.”

The three selected postdoctoral fellows are focused on researching within space health — specifically reducing the health risks associated with spaceflight. They will receive a two-year salary stipend and participate in TRISH’s Academy of Bioastronautics, a mentorship community for space health professionals.

“Pursuing my postdoctoral training at TRISH has accelerated my career and expanded my research portfolio, enabling me to make new connections and become a more well-rounded scientist,” says Dr. Evan Buettmann, a TRISH third-year postdoctoral fellow at Virginia Commonwealth University, in the release. “Having completed my Ph.D. in bone regeneration, I didn’t initially anticipate that my studies would lead me to an academic career in space health. TRISH stood out to me as an excellent place to complete my postdoctoral training, as it’s at the cutting edge of both space science and medicine and offers extensive mentorship and leadership opportunities.”

This 2023 cohort of fellows include:

  • Stephanie Dudzinski, M.D., Ph.D. Her research focuses on extending healthy life in space by characterizing radiation-induced pro-inflammatory response and enhancing wound repair and recovery with radiation- mitigating thrombin peptide. Her mentor is Steven Frank, M.D., of the University of Texas MD Anderson Cancer Center.
  • Adrien Robin, Ph.D., who is looking at the effect of deconditioning on-gravitational dose-response curves for cardiovascular and ocular variables in men and women and is being mentored by Ana Diaz Artiles, Ph.D., Texas A&M Engineering Experiment Station.
  • Katherine Wozniak, Ph.D., who is defining gut microbial changes to space-like radiation to develop a radiation-resistant microbiome. Her mentor is Robert Britton, Ph.D., of Baylor College of Medicine.
In addition to supporting scientists through its fellowship program, TRISH is actively conducting research aboard commercial space flights — most recently with Axiom Space's Ax-2 mission..
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston doctor aims to revolutionize hearing aid industry with tiny implant

small but mighty

“What is the future of hearing aids?” That’s the question that led to a potential revolution.

“The current hearing aid market and technology is old, and there are little incremental improvements, but really no significant, radical new ideas, and I like to challenge the status quo,” says Dr. Ron Moses, an ENT specialist and surgeon at Houston Methodist.

Moses is the creator of NanoEar, which he calls “the world’s smallest hearing aid.” NanoEar is an implantable device that combines the invisibility of a micro-sized tympanostomy tube with more power—and a superior hearing experience—than the best behind-the-ear hearing aid.

“You put the NanoEar inside of the eardrum in an in-office procedure that takes literally five minutes,” Moses says.

As Moses explains, because of how the human cochlea is formed, its nerves break down over time. It’s simply an inevitability that if we live long enough, we will need hearing aids.

“The question is, ‘Are we going to all be satisfied with what exists?’” he asks.

Moses says that currently, only about 20 percent of patients who need hearing aids have them. That’s because of the combination of the stigma, the expense, and the hassle and discomfort associated with the hearing aids currently available on the market. That leaves 80 percent untapped among a population of 466 million people with hearing impairment, and more to come as our population ages. In a nearly $7 billion global market, that additional 80 percent could mean big money.

Moses initially patented a version of the invention in 2000, but says that it took finding the right team to incorporate as NanoEar. That took place in 2016, when he joined forces with cofounders Michael Moore and Willem Vermaat, now the company’s president and CFO, respectively. Moore is a mechanical engineer, while Vermaat is a “financial guru;” both are repeat entrepreneurs in the biotech space.

Today, NanoEar has nine active patents. The company’s technical advisors include “the genius behind developing the brains in this device,” Chris Salthouse; NASA battery engineer Will West; Dutch physicist and audiologist Joris Dirckx; and Daniel Spitz, a third-generation master watchmaker and the original guitarist for the famed metal band Anthrax.

The NanoEar concept has done proof-of-concept testing on both cadavers at the University of Antwerp and on chinchillas, which are excellent models for human hearing, at Tulane University. As part of the TMC Innovation Institute program in 2017, the NanoEar team met with FDA advisors, who told them that they might be eligible for an expedited pathway to approval.

Thus far, NanoEar has raised about $900,000 to get its nine patents and perform its proof-of-concept experiments. The next step is to build the prototype, but completing it will take $2.75 million of seed funding.

Despite the potential for making global change, Moses has said it’s been challenging to raise funds for his innovation.

“We're hoping to find that group of people or person who may want to hear their children or grandchildren better. They may want to join with others and bring a team of investors to offset that risk, to move this forward, because we already have a world-class team ready to go,” he says.

To that end, NanoEar has partnered with Austin-based Capital Factory to help with their raise. “I have reached out to their entire network and am getting a lot of interest, a lot of interest,” says Moses. “But in the end, of course, we need the money.”

It will likely, quite literally, be a sound investment in the future of how we all hear the next generation.

Houston VC funding surged in Q1 2025 to highest level in years, report says

by the numbers

First-quarter funding for Houston-area startups just hit its highest level since 2022, according to the latest PitchBook-NVCA Venture Monitor. But fundraising in subsequent quarters might not be as robust thanks to ongoing economic turmoil, the report warns.

In the first quarter of 2025, Houston-area startups raised $544.2 million in venture capital from investors, PitchBook-NVCA data shows. That compares with $263.5 million in Q1 2024 and $344.5 million in Q1 2023. For the first quarter of 2022, local startups nabbed $745.5 million in venture capital.

The Houston-area total for first-quarter VC funding this year fell well short of the sum for the Austin area (more than $3.3 billion) and Dallas-Fort Worth ($696.8 million), according to PitchBook-NVCA data.

While first-quarter 2025 funding for Houston-area startups got a boost, the number of VC deals declined versus the first quarters of 2024, 2023 and 2022. The PitchBook-NVCA Monitor reported 37 local VC deals in this year’s first quarter, compared with 45 during the same period in 2024, 53 in 2023, and 57 in 2022.

The PitchBook-NVCA report indicates fundraising figures for the Houston area, the Austin area, Dallas-Fort Worth and other markets might shrink in upcoming quarters.

“Should the latest iteration of tariffs stand, we expect significant pressure on fundraising and dealmaking in the near term as investors sit on the sidelines and wait for signs of market stabilization,” the report says.

Due to new trade tariffs and policy shifts, the chances of an upcoming rebound in the VC market have likely faded, says Nizar Tarhuni, executive vice president of research and market intelligence at PitchBook.

“These impacts amplify economic uncertainty and could further disrupt the private markets by complicating investment decisions, supply chains, exit windows, and portfolio strategies,” Tarhuni says. “While this may eventually lead to new domestic investment and create opportunities, the overall environment is facing volatility, hesitation, and structural change.”